Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
epimastigotes
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "epimastigotes" in MCE Product Catalog:
1
Category:
Cardiovascular Disease Neurological Disease Capsicum annuum L. Extract Solanaceae Extract Infection Alkaloids Plant Other Alkaloids Disease Research Fields Inflammation/Immunology
Target:
Cat. No.: HY-N7632
CAS No.: 21763-80-4
Category:
Flavones Compositae/Asteraceae Extract Other Families Extract Infection Plant Flavonoids Monophenols Artemisia princeps Pamp. Extract Phenols Disease Research Fields Inflammation/Immunology
Target:
Target:
Cat. No.: HY-115972
CAS No.: 2863602-85-9
Target:
Research Areas:
Anti-Trypanosoma cruzi agent-1 (Compd 3b), selective compound against NINOA trypomastigote (IC50 = 0.51 µM) and INC-5 epimastigote form (IC50 = 3.06 µM), posseses anti-T. gondii activity .
Cat. No.: HY-120550
CAS No.: 111962-89-1
RS 49676 is an N-substituted imidazole compound that exhibits strong in vitro activity against endogenous amoebae (ED50 < 0.1 ng/mL), but is ineffective against exogenous amoebae (epimastigotes). In vivo, RS 49676 (100 mg/kg/d, sc, 2 times) can prolong the average survival time of mice infected with Trypanosoma cruzi to more than 11 weeks.
Cat. No.: HY-126562R
CAS No.: 5950-12-9
Cat. No.: HY-184345
CAS No.: 332858-46-5
(+)-Cyclozonarone is a benzoquinone derivative found in brown algae Dictyopteris undulata, with activity against T. cruzi epimastigotes, Tulahuen strains. (+)-Cyclozonarone inhibits growth of cancer and endothelial cells, and exhibits anti-leishmanial activity. (+)-Cyclozonarone can be used for the research of lung carcinoma, colon carcinoma, prostate carcinoma .
Cat. No.: HY-112453
CAS No.: 623163-52-0
IMDNQ1 is a Trypanosoma cruzi inhibitor derived from 1,4-naphthoquinone substituted with cyclic imide. IMDNQ1 effectively inhibits the proliferation of Trypanosoma cruzi epimastigotes, while also reducing the viability of mouse fibroblasts. The selectivity index between the antiproliferative activity and cytotoxicity of IMDNQ1 is 60.25, indicating a certain level of safety. IMDNQ1 can be widely used in studies related to Chagas disease .
Cat. No.: HY-123746
CAS No.: 332132-39-5
Target:
Research Areas:
E5700 is an orally active squalene synthase inhibitor, antimalarial agent and antifungal agent with an IC50 of 0.49 nM (without PPi) against squalene synthase from T. cruzi epimastigotes. E5700 shows antiparasitic activities against Trypanosoma cruzi. E5700 inhibits the growth and alters the lipid prolife and the ultrastructure of a multiple agent-resistant C. tropicalis strain. E5700 is a potent and selective inhibitor of the growth of Leishmania amazonensis .
Cat. No.: HY-182516
CAS No.: 32545-60-1
Target:
Aminobutane bisphosphonate is a Trypanosoma cruzi farnesyl pyrophosphate synthase (FPPS) inhibitor with an IC50 of 30.77 μM against Trypanosoma cruzi. Aminobutane bisphosphonate inhibits proliferation of intracellular amastigote Trypanosoma cruzi and lacks activity against non-infective epimastigote forms. Aminobutane bisphosphonate reduces osteoclastic bone resorption, osteoid surface extent, and osteoclast number per mm of bone surface. Aminobutane bisphosphonate can be used for the research of american trypanosomiasis (chagas' disease) and immobilization-related bone loss .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
